Greg Rhee, PhD, FACE
Associate Professor Adjunct in PsychiatryCards
Contact Info
About
Titles
Associate Professor Adjunct in Psychiatry
Biography
Greg Rhee, PhD, FACE, is Associate Professor of Medicine (Psychiatry) and Public Health (Epidemiology and Biostatistics). He is a pharmaco-epidemiologist and mental health services researcher studying access to care, quality of care, and clinical and patient-reported outcomes in patients with psychiatric and/or substance use disorders. His current research focuses on mood disorders, dementias, and suicide/suicidal behaviors as well as cannabis and opioids.
As an accredited professional statistician (PStat®) certified by the American Statistical Association, his expertise is grounded in (1) population-based observational studies using large databases; (2) systematic reviews and meta-analyses of existing studies; and (3) analyses of clinical trial data. In particular, he has extensive knowledge and experience with administrative claims data (e.g., Medicare and Medicaid), national health and healthcare survey data, and other data sources including electronic health records (e.g., Epic® database from Yale-New Haven Health), RCT data, and mortality data. He also investigates long-term comparative effectiveness and cost-effectiveness of pharmacological and non-pharmacological interventions for psychiatric and/or substance use disorders.
He has 200+ peer-reviewed research articles published in highly respected medical, psychiatric, and healthcare policy journals, such as Lancet, Lancet Neurology, JAMA, JAMA Psychiatry, and American Journal of Psychiatry. He has also been a successful Principal Investigator or Co-Investigator on multiple research projects funded by federal agencies, including Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA), and National Institutes of Health (NIH).
Outside Yale Psychiatry, he also serves as an Investigator at the VA Connecticut Healthcare System VISN 1 MIRECC.
Education & Training
- NIH Postdoctoral Fellowship
- Yale University School of Medicine (2019)
- PhD
- University of Minnesota, Twin Cities (2017)
- MA
- The University of Chicago (2011)
- AB
- Emory University (2008)
Research
Overview
Medical Research Interests
Public Health Interests
ORCID
0000-0003-4961-3361
Research at a Glance
Yale Co-Authors
John Havlik, MD, MBA
Rajiv Radhakrishnan, MBBS, MD, FAPA
Samuel Wilkinson, MD
Sina Nikayin, MD
Publications
2024
Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials
Meshkat S, Kwan A, Le G, Wong S, Teopiz K, Wang L, Rosenblat J, Rhee T, Cao B, McIntyre R. Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials. Journal Of Affective Disorders 2024 PMID: 39638064, DOI: 10.1016/j.jad.2024.12.008.Peer-Reviewed Original ResearchAltmetricConceptsOrexin receptor antagonistsHamilton Depression Rating ScaleDepression Rating ScaleDepressive disorderQuick Inventory of Depressive Symptomatology Self-ReportReceptor antagonistInventory of Depressive Symptomatology Self-ReportDepressive symptoms compared to placeboMontgomery-Asberg Depression Rating ScaleRating ScaleDepressive Symptomatology Self-ReportMADRS total scoreSymptoms compared to placeboTreatment of depressionDecreased depression scoresQIDS-SRMDD patientsMontgomery-AsbergManaging depressive symptomsRandomized clinical trialsOrexin antagonistsDepression treatmentDepressive symptomsTreating insomniaCompared to placeboA systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
Menon T, Lee S, Gong X, Wong S, Le G, Kwan A, Teopiz K, Ho R, Cao B, Rhee T, Jing Zheng Y, Valentino K, Lin K, Vinberg M, Lo H, McIntyre R. A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain. CNS Spectrums 2024, 1-7. PMID: 39582175, DOI: 10.1017/s1092852924000531.Peer-Reviewed Original ResearchAltmetricConceptsPsychiatric medicationsEffects of GLP-1RAsReceptor agonistsEfficacy of GLP-1 receptor agonistsRandomized controlled trialsGLP-1RAsModerate weight changeMitigate weight gainPsychiatric populationsPsychotropic drugsCognitive processesWeight gainClinically meaningful effectGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsSystematic reviewPreliminary evidenceGlucose-lowering agentsLong-term safetyWeight changeMeaningful effectEfficacy profilePersonsAbnormal weightClinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale.
Kaster T, Babujee A, Sharpe I, Rhee T, Gomes T, Kurdyak P, Foussias G, Wijeysundera D, Blumberger D, Vigod S. Clinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale. The Canadian Journal Of Psychiatry 2024, 7067437241290181. PMID: 39529283, PMCID: PMC11562932, DOI: 10.1177/07067437241290181.Peer-Reviewed Original ResearchAltmetricConceptsSchizophrenia spectrum disordersInpatient electroconvulsive therapySeverity of psychotic symptomsAdministration of electroconvulsive therapyElectroconvulsive therapyPsychotic symptomsPatient-level characteristicsDiagnosis of schizophrenia spectrum disorderRates of substance use disordersObsessive-compulsive disorderSymptoms of psychosisAnti-psychotic medicationPopulation-level cross-sectional studySubstance use disordersOutpatient mental health service useEvidence-based treatmentsMental health service usePresence of catatoniaHealth service useClinical characteristicsPsychiatric inpatientsCharacteristics of inpatientsClinical characteristics of inpatientsComorbid depressionMulti-variable logistic regressionA systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders
Au H, Zheng Y, Le G, Wong S, Phan L, Teopiz K, Kwan A, Rhee T, Rosenblat J, Ho R, McIntyre R. A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders. Journal Of Affective Disorders 2024, 370: 321-327. PMID: 39515485, DOI: 10.1016/j.jad.2024.11.019.Peer-Reviewed Original ResearchAltmetricConceptsDorsal default mode networkFunctional connectivityMental disordersAssociated with decreased functional connectivityAssociated with increased functional connectivityRight frontal-parietal networkLateral orbitofrontal cortexFrontal-parietal networkDefault mode networkIncreased functional connectivityBrain functional connectivityBrain functional activityGlucagon-like peptide-1Orbitofrontal cortexPsychopathological domainsSalience networkVisuospatial networkMode networkParietal networkPsychiatric disordersBrain circuitsNeural circuitsGLP-1RAsGlucagon-like peptide-1 receptor activationReceptor agonistsEfficacy of esketamine for perinatal depression: a systematic review and meta-analysis.
Wong S, Le G, Kwan A, Teopiz K, Rhee T, Ho R, Rosenblat J, Mansur R, McIntyre R. Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis. CNS Spectrums 2024, 1-9. PMID: 39479775, DOI: 10.1017/s1092852924000452.Peer-Reviewed Original ResearchAltmetricConceptsPostpartum depressionPerinatal depressionPrevention of postpartum depressionIncidence of postpartum depressionReduced health-related quality of lifeHealth-related quality of lifeSystematic reviewTreatment of postpartum depressionWeeks of childbirthMeta-analysisWeeks post-deliveryClinically meaningful implicationsQuality of lifeRandomized controlled trialsRandom-effects modelDecreased incidencePain managementPostpartum periodChildbirth laborIncidence ratePost-deliveryPsychosocial functioningEligibility criteriaControlled trialsPrimary outcomeNational Trends in and Concentration of Industry Payments to U.S. Psychiatrists, 2015-2021.
Havlik J, Ososanya L, Tang D, Wahid S, Ross J, Rhee T. National Trends in and Concentration of Industry Payments to U.S. Psychiatrists, 2015-2021. Psychiatric Services 2024, appips20240218. PMID: 39439279, DOI: 10.1176/appi.ps.20240218.Peer-Reviewed Original ResearchAltmetricGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)
McIntyre R, Mansur R, Rosenblat J, Rhee T, Cao B, Teopiz K, Wong S, Le G, Ho R, Kwan A. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®). Journal Of Affective Disorders 2024, 369: 922-927. PMID: 39433133, DOI: 10.1016/j.jad.2024.10.062.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGLP-1 RAsReporting Odds RatioFood and Drug AdministrationFDA Adverse Event Reporting SystemGLP-1European Medicines AgencyMeasures of suicidalityWorld Health OrganizationGlucagon-like peptide-1 receptor agonistsGlucagon-like peptide 1 receptor agonistsWorld Health Organization pharmacovigilance databasePeptide-1 receptor agonistsPeptide 1 receptor agonistsUnited States Food and Drug AdministrationRA exposureStates Food and Drug AdministrationSuicidal behaviorSuicidal ideationAdverse Event Reporting SystemSuicideReceptor agonistsEvent Reporting SystemSemaglutideOdds ratioPharmacovigilance databaseEfficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsBipolar depressionAcute seriesRisk of affective switchDiagnosis of bipolar depressionRefractory bipolar depressionAcute phaseMADRS scoreAffective switchIntranasal esketamineManic episodesBipolar disorderCohort of patientsAttending psychiatristsSource of morbidityEsketamineSample of patientsIV ketamineMaintenance treatmentDepressionClinical responseHeightened riskClinical outcomesMania/hypomaniaKetamineKetamine/esketamineCorrection: Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial
Kwan A, Lakhani M, Le G, Singh G, Teopiz K, Ceban F, Nijjar C, Meshkat S, Badulescu S, Ho R, Rhee T, Di Vincenzo J, Gill H, McIntyre R. Correction: Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial. European Archives Of Psychiatry And Clinical Neuroscience 2024, 274: 1967-1968. PMID: 39307886, DOI: 10.1007/s00406-024-01910-z.Peer-Reviewed Original ResearchElectroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
Le G, Wong S, Lu A, Vasudeva S, Gill H, Badulescu S, Portelles D, Zheng Y, Teopiz K, Meshkat S, Kwan A, Ho R, Rhee T, Rosenblat J, Mansur R, McIntyre R. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review. Journal Of Affective Disorders 2024, 368: 798-819. PMID: 39299586, DOI: 10.1016/j.jad.2024.09.081.Peer-Reviewed Original ResearchAltmetricConceptsReuptake inhibitorsDepressive disorderPathophysiology of depressive disordersSystematic reviewAssociated with SSRIsClass of SSRIsNorepinephrine reuptake inhibitorsDoses of antidepressantsSerotonin reuptake inhibitorsFDA-approved agentsVortioxetine treatmentBlock reuptakeAntidepressant exposureSerotonin transporterSNRISSRIsVortioxetineDatabase inceptionConverging evidenceFunctional connectivitySerotoninNeural activityElectroencephalography signaturesStudy investigated changesInhibitors
Academic Achievements & Community Involvement
activity Journal of Clinical Psychiatry
Journal ServiceEditorial Board MemberDetails06/01/2022 - Presentactivity Depression and Anxiety
Journal ServiceAssociate EditorDetails10/01/2022 - Presentactivity American Journal of Geriatric Psychiatry
Journal ServiceEditorial Board MemberDetails2023 - Presentactivity National Institutes of Health Center for Scientific Review (CSR) - Study Section
Peer Review Groups and Grant Study SectionsCommittee MemberDetails2023 - Presenthonor Delta Omega Honorary Society in Public Health
International AwardDelta Omega (Faculty Mentor)Details05/05/2023
News
News
- October 24, 2024Source: Psychiatric Services
National Trends in and Concentration of Industry Payments to U.S. Psychiatrists, 2015–2021
- October 02, 2024
Bipolar Disorder Patients Respond to Ketamine, Esketamine Treatment
- June 04, 2024Source: The American Journal of Psychiatry
National Trends in Emergency Department Visits for Suicide Attempts and Intentional Self-Harm
- May 03, 2024Source: PLOS ONE
Association of Mental Health Related Quality of Life and Other Factors with Treatment Seeking for Substance Use Disorders: A Comparison of SUDs Rooted in Legal, Partially Legal, and Illegal Substances
Get In Touch
Contacts
Locations
E.S. Harkness Memorial Hall, Building A
Academic Office
367 Cedar Street, Rm 308
New Haven, CT 06510